Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS)

References

• Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU. Arch Osteoporos 2011;6:59-155
   PubMedGoogle Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidelines for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57
   PubMed Web of Science ®Google Scholar
• Kaufman J-M, Reginster JY, Boonen S, et al. Treatment of osteoporosis in men. Bone 2013;53:134-44
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-21
   PubMed Web of Science ®Google Scholar
• Kanis J, Compston J, Cooper C, et al. The economic burden of fractures in the European Union in 2010. Osteoporos Int 2012;23(Suppl 2):S57-84
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, et al. Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
   PubMed Web of Science ®Google Scholar
• Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007;22:149-57
   PubMed Web of Science ®Google Scholar
• Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009;24:726-36
   PubMed Web of Science ®Google Scholar
• Graeff C, Chevalier Y, Charlebois M, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 2009;24:1672-80
   PubMed Web of Science ®Google Scholar
• Borggrefe J, Graeff C, Nickelsen TN, et al. Quantitative computed tomography assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 2010;25:472-81
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Teriparatide. Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000425/WC500027994.pdf [Last accessed 8 October 2013]
   Google Scholar
• Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005;16:510-16
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60:3346-55
   PubMed Web of Science ®Google Scholar
• Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008;24:377-84
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85:484-93
   PubMed Web of Science ®Google Scholar
• Fahrleitner-Pammer A, Langdahl BL, Marin F, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 2011;22:2709-19
   PubMed Web of Science ®Google Scholar
• Jakob F, Oertek H, Langdahl B, et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 2012;166:87-97
   PubMed Web of Science ®Google Scholar
• Silverman S, Miller P, Sebba A, et al. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int 2013;24:2309-17
   PubMed Web of Science ®Google Scholar
• Sriwatanakul K, Kelvie W, Lasagna L, et al. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983;34:234-9
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72
   PubMed Web of Science ®Google Scholar
• Szende A, Williams A, eds. Measuring self-reported health: an international perspective based on EQ-5D. Rotterdam, The Netherlands: EuroQol, 2004. Available at: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Books/Measuring_Self-Reported_Population_Health_-_An_International_Perspective_based_on_EQ-5D.pdf [Last accessed 26 September 2013]
   Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 2012;23:2257-76
   PubMed Web of Science ®Google Scholar
• Janssen MF, Lubetkin EL, Sekhobo JP, et al. The use of EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. Diabet Med 2011;28:395-413
   PubMed Web of Science ®Google Scholar
• Dyer MT, Goldsmith KA, Sharples LS, et al. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 2010;8:13
   PubMed Web of Science ®Google Scholar
• Pickard AS, Wilke CT, Lin HW, et al. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007;25:365-84
   PubMed Web of Science ®Google Scholar
• Lyritis G, Marin F, Barker C, et al; EUROFORS Study Group. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Curr Med Res Opin 2010;26:1799-807
   PubMed Web of Science ®Google Scholar
• Silverman SL, Piziak VK, Chen P, et al. Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 2005;32:2405-9
   PubMed Web of Science ®Google Scholar
• Adami S, Maugeri D, Toscano V, et al. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO). Clin Exp Rheumatol 2011;29:477-84
   PubMed Web of Science ®Google Scholar
• Ish-Shalom S, Dumitrache C, El-Husseini TF, et al. Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice. Curr Med Res Opin 2011;27:343-53
   PubMed Web of Science ®Google Scholar
• Cooper C, Jakobs F, Chinn C, et al. Fracture incidence and changes in quality of life in women with an inadequate clinical outcome form osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 2008;19:493-501
   PubMed Web of Science ®Google Scholar
• Wilson S, Sharp CA, Davie MW. Health-related quality of life in patients with osteoporosis in the absence of vertebral fracture: a systematic review. Osteoporos Int 2012;23:2749-68
   PubMed Web of Science ®Google Scholar
• Lau AN, Ali SH, Sawka AM, et al. Improvement in health-related quality of life in osteoporosis patients treated with teriparatide. BMC Musculoskelet Disord 2008;9:151
   PubMed Web of Science ®Google Scholar
• Ljunggen O, Barrett A, Stoykov I, et al. Effective osteoporosis treatment with teriparatide is associated with quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study (EFOS). BMC Musculoskelet Disord 2013;14:251
   PubMed Web of Science ®Google Scholar
• Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14:185-97
   PubMed Web of Science ®Google Scholar
• Gluer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013;28:1355-68
   PubMed Web of Science ®Google Scholar
• Graeff C, Marin F, Petto H, et al. High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis. Bone 2013;52:568-77
   PubMed Web of Science ®Google Scholar
• Wong M, Wan X, Ruff V, et al. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fractures in the Community Experience (DANCE) study. Osteoporos Int 2012;23:1445-52
   PubMed Web of Science ®Google Scholar